Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.51), $0.06 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $57.1 million versus the consensus estimate of $58.63 million.

GUIDANCE:

ACADIA is lowering its 2018 NUPLAZID net sales guidance to be between $210 million and $225 million from a previous range of $255 million to $270 million.

For the third quarter of 2018, ACADIA expects NUPLAZID net sales to be between $52 million and $59 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.